脓毒性休克患者脓毒性心肌病的预后影响与危险因素:一项观察性研究
该回顾性观察研究纳入2022年12月至2024年7月北京同仁医院收治的108例脓毒性休克患者,按有无脓毒性心肌病分为非脓毒性心肌病组(n=90)和脓毒性心肌病组(n=18)。脓毒性心肌病组尿路感染和糖尿病史比例更高,APACHE II评分和序贯器官衰竭评估评分更高,入院当天肌钙蛋白I、白细胞介素-1、肿瘤坏死因子-α、最大乳酸、最大脑钠肽和峰值肌钙蛋白I更高,入院平均动脉压、最低左心室射血分数和终点左心室射血分数更低。多变量logistic回归显示,白细胞介素-1升高(OR=1.14)、APACHE II评分升高(OR=1.13)和最大乳酸升高(OR=1.47)是脓毒性心肌病的危险因素。脓毒性心肌病与院内死亡率升高和医疗费用增加相关,且在脓毒性心肌病患者中,左心室射血分数和心输出量恢复与生存改善相关。
要点
- 脓毒性休克患者中脓毒性心肌病发生率为16.67%(18/108),脓毒性心肌病组院内死亡率显著高于非脓毒性心肌病组(P<0.05)。
- 多变量logistic回归显示,白细胞介素-1升高(OR=1.14)、APACHE II评分升高(OR=1.13)和最大乳酸升高(OR=1.47)是脓毒性休克的脓毒性心肌病危险因素(P<0.05)。
- 脓毒性心肌病组尿路感染比例和糖尿病史比例显著高于非脓毒性心肌病组(P<0.05)。
- 脓毒性心肌病组入院当天肌钙蛋白I、白细胞介素-1、肿瘤坏死因子-α、最大乳酸、最大脑钠肽和峰值肌钙蛋白I均显著高于非脓毒性心肌病组,入院平均动脉压、最低左心室射血分数和终点左心室射血分数显著低于非脓毒性心肌病组(P<0.05)。
- 在脓毒性心肌病患者中,左心室射血分数和心输出量恢复与生存改善相关,作者认为可能作为临床结局的有价值指标。
适用人群与场景
- 2022年12月至2024年7月北京同仁医院收治的脓毒性休克患者108例,按有无脓毒性心肌病分为非脓毒性心肌病组(n=90)和脓毒性心肌病组(n=18)。
研究设计与关键结果
- 回顾性观察研究,纳入108例脓毒性休克患者,脓毒性心肌病发生率为16.67%(18/108)。
- 与非脓毒性心肌病组相比,脓毒性心肌病组尿路感染比例和糖尿病史比例显著更高(P<0.05)。
- 脓毒性心肌病组APACHE II评分和序贯器官衰竭评估评分显著更高,入院当天肌钙蛋白I、白细胞介素-1、肿瘤坏死因子-α、最大乳酸、最大脑钠肽和峰值肌钙蛋白I显著更高(P<0.05)。
- 脓毒性心肌病组入院平均动脉压、最低左心室射血分数和终点左心室射血分数显著低于非脓毒性心肌病组(P<0.05)。
- 多变量logistic回归显示,白细胞介素-1升高(OR=1.14)、APACHE II评分升高(OR=1.13)和最大乳酸升高(OR=1.47)是脓毒性心肌病的危险因素(P<0.05)。
- 脓毒性心肌病与院内死亡率升高和医疗费用增加显著相关(P<0.05)。
- 在脓毒性心肌病患者中,左心室射血分数和心输出量恢复与生存改善相关。
证据类型、等级与局限
- 证据类型:回顾性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对脓毒性休克患者,白细胞介素-1升高、APACHE II评分升高和最大乳酸升高与脓毒性心肌病发生相关,脓毒性心肌病与院内死亡率升高和医疗费用增加相关。
- 在脓毒性心肌病患者中,左心室射血分数和心输出量恢复与生存改善相关,作者认为可能作为临床结局的有价值指标。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: This study aims to identify risk factors associated with septic cardiomyopathy (SCM) in patients diagnosed with septic shock and to assess differences in clinical outcomes between those with septic shock alone and those with concomitant SCM.
METHODS: A retrospective observational study was conducted on 108 patients diagnosed with septic shock and admitted to Beijing Tongren Hospital, Capital Medical University, between December 2022 and July 2024. Patients were stratified into two groups based on the presence or absence of SCM: the non-SCM group (n = 90) and the SCM group (n = 18). Baseline characteristics, laboratory markers, cardiac function indices, and clinical outcomes were compared between the two groups. Multivariate logistic regression was employed to identify risk factors for SCM. Within the SCM group, outcomes were further analyzed according to survival status to assess the association between cardiac function recovery and mortality.
RESULTS: The incidence of SCM among patients with septic shock was 16.67%. Compared with the non-SCM group, the SCM group showed a significantly higher prevalence of urinary tract infections and a history of diabetes mellitus ( P < 0.05). Higher scores were observed for the Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment scales, along with increased levels of admission-day troponin I, interleukin-1 (IL-1), tumor necrosis factor-α, maximum lactic acid (LACmax), maximum brain natriuretic peptide, and peak troponin I ( P < 0.05). In contrast, mean arterial pressure at admission, minimum left ventricular ejection fraction (LVEF), and end-point LVEF (LVEFend%) were significantly lower in this group ( P < 0.05). Multivariate logistic regression identified elevated IL-1 levels (odds ratio [OR] = 1.14), higher APACHE II scores (OR = 1.13), and increased LACmax (OR = 1.47) as risk factors for SCM ( P < 0.05). The presence of SCM was associated with significantly higher in-hospital mortality and increased healthcare costs ( P < 0.05). Among patients with SCM, recovery of LVEF and cardiac output was correlated with improved survival outcomes.
CONCLUSIONS: Elevated IL-1 levels, increased peak lactic acid concentration, and higher APACHE II scores were associated with the development of SCM in patients with septic shock. SCM was further associated with increased mortality and greater healthcare resource utilization. Restoration of cardiac function, particularly improvements in LVEF and cardiac output, was correlated with improved prognosis and may serve as a valuable indicator of clinical outcomes.
参考来源
- Xu RM, Wang DW, Wang L, et al. Prognostic Impact and Risk Factors of Septic Cardiomyopathy in Patients with Septic Shock: An Observational Study. Shock. 2025. PMID: 41670969. doi:10.1097/SHK.0000000000002782
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。